Previous 10 | Next 10 |
Eagle Pharmaceuticals, Inc. (EGRX) Q1 2020 Results Earnings Conference Call May 11, 2020, 08:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - Chief Executive Officer Pete Meyers - Chief Financial Officer David Pernock - President and COO Adrian H...
Image source: The Motley Fool. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) Q1 2020 Earnings Call May 11, 2020 , 8:30 a.m. ET Operator Continue reading
Eagle Pharmaceuticals (NASDAQ: EGRX ): Q1 Non-GAAP EPS of $0.84 beats by $0.27 ; GAAP EPS of -$0.21 misses by $0.40 . More news on: Eagle Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Q1 2020 net loss was ($0.21) per basic and diluted share and adjusted non-GAAP net income was $0.86 per basic and $0.84 per diluted share -- -- Advanced novel fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor (“ER”) inhibition i...
Eagle Pharmaceuticals (NASDAQ: EGRX ) provides an update on its pilot clinical study to assess the unique characteristics of fulvestrant product candidate, EA-114. More news on: Eagle Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today provided an update on its pilot clinical study to assess the unique characteristics of its fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor ( ...
Teva Receives Positive Ruling on Cancer Drug Patents Teva Pharmaceuticals Industries Ltd. ( TEVA ) received a boost as it received positive ruling on its Bendeka cancer drug. The ruling may ensure that the drug is not thwarted by generic competition in the market for a considerable period...
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 first quarter financial results on Monday, May 11, 2020, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyer...
Eagle Pharmaceuticals (NASDAQ: EGRX ) and licensee Teva Pharmaceutical Industries (NYSE: TEVA ) announce a favorable outcome in a patent dispute from would-be generic competitors to blood cancer med Bendeka (bendamustine HCl) injection. More news on: Eagle Pharmaceuticals, Inc., Teva Pha...
-- Further Protects Longevity of BENDEKA franchise -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (“Teva”) announced today that on April 27, 2020, the U.S. Distric...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...